Erdafitinib (Boke) belongs to which generation of targeted drugs and its differences from similar drugs

Erdafitinib is an oral FGFR (fibroblast growth factor receptor) inhibitor that is generally classified as a second-generation targeted drug. Its main mechanism of action is to selectively inhibit FGFR1-4 and block abnormal signaling pathways, thereby inhibiting the proliferation and angiogenesis of tumor cells. Compared with the earlier generation of targeted drugs, erdafitinib has been significantly optimized in target selectivity and pharmacokinetics, and can act on cancer-causing mutations more accurately and improve therapeutic effects.

Compared with first-generation targeted drugs, erdafitinib performs better in covering resistance mutations. Most of the first-generation FGFR inhibitors are broad-spectrum inhibitors, which are not precise enough in targeting and can easily cause side effects on normal cells. By optimizing the molecular structure, erdafitinib has a stronger inhibitory effect on FGFR mutations, especially FGFR2/3 fusions and point mutations, while reducing the inhibition of non-target sites and reducing the risk of toxic side effects.

Compared with third-generation targeted drugs, erdafitinib is slightly inferior in its ability to inhibit some drug-resistant mutations. Third-generation targeted drugs are usually designed to target specific resistance mechanisms, such as high-affinity inhibition of ATP binding pocket mutations. Despite this, erdafitinib can still cover most common FGFR mutations clinically, and is particularly suitable for patients with bladder cancer and other FGFR-driven tumors.

In general, the advantages of erdafitinib as a second-generation targeted drug are high selectivity, good tolerability, and clinical data supporting a wide range of indications. Compared with similar drugs, it focuses more on accurately targeting mutations to reduce side effects, while providing reliable treatment options and new clinical options for patients with FGFR-driven tumors.

Keyword tags:

Erdafitinib, FGFR inhibitor, second-generation targeted drug, bladder cancer, target selectivity, drug resistance coverage, adverse reactions

Reference materials:https://www.cancer.gov/about-cancer/treatment/drugs/erdafitinib